Beigene (NASDAQ:ONC) Stock Price Down 7.7% – What’s Next?

Beigene, Ltd. (NASDAQ:ONC)’s share price traded down 7.7% during trading on Monday . The company traded as low as $214.12 and last traded at $220.03. 219,944 shares changed hands during trading, a decline of 52% from the average session volume of 459,486 shares. The stock had previously closed at $238.51.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and lifted their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada assumed coverage on Beigene in a research report on Monday. They set an “outperform” rating and a $312.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Beigene in a report on Friday, February 28th. JMP Securities set a $348.00 target price on shares of Beigene in a report on Friday, February 28th. Finally, Macquarie increased their price target on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th.

Beigene Stock Performance

The company has a fifty day moving average of $251.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The firm has a market capitalization of $21.76 billion, a price-to-earnings ratio of -26.76, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49.

Beigene (NASDAQ:ONC) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, sell-side analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insider Buying and Selling at Beigene

In related news, COO Xiaobin Wu sold 51,921 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Oyler sold 101,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $244.30, for a total value of $24,674,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,104,288 shares of company stock valued at $285,064,819 in the last three months. 7.43% of the stock is currently owned by company insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.